Fundamental XR expands access to immersive training with web-enabled platform

Tern plc

Fundamental XR has launched Immersive Web, a platform designed to extend immersive training beyond headset-only environments and into the browser.

The company’s core proposition has centred on delivering high-fidelity, hands-on training through virtual environments. While immersive hardware enables realistic and repeatable skill development, full deployment can require logistical planning, capital investment and on-site coordination. Immersive Web introduces a browser-based layer that allows elements of training to be accessed without dedicated equipment, widening the potential user base and reducing friction at the point of entry.

This approach alters the economics of implementation. Organisations can begin engagement through standard web browsers, enabling learners to complete preparatory modules, theoretical instruction and guided walkthroughs before progressing to fully immersive simulations. By separating foundational learning from advanced practical application, the platform supports a more staged investment model.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Search